MIT 003
Alternative Names: MIT-003Latest Information Update: 08 Feb 2023
At a glance
- Originator MitoImmune Therapeutics
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Parkinson's disease
Most Recent Events
- 05 Jan 2023 Preclinical trials in Alzheimer's disease in South Korea (PO) before January 2023 (MitoImmune Therapeutics pipeline, January 2023)
- 05 Jan 2023 Preclinical trials in Parkinson's disease in South Korea (PO) before January 2023 (MitoImmune Therapeutics pipeline, January 2023)